Magdalena Izabela Zakrzewska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/395695/publications.pdf Version: 2024-02-01



MAGDALENA IZABELA

#	Article	IF	CITATIONS
1	mRNA and miRNA Expression Analyses of the MYC/E2F/miR-17-92 Network in the Most Common Pediatric Brain Tumors. International Journal of Molecular Sciences, 2021, 22, 543.	4.1	11
2	microRNA interaction with MAPK and AKT pathways in paediatric brain tumours – preliminary results and review of the literature. Folia Neuropathologica, 2020, 58, 123-132.	1.2	5
3	Sensitive detection of <i>FGFR1 N546K</i> mosaic mutation in patient with encephalocraniocutaneous lipomatosis and pilocytic astrocytoma. American Journal of Medical Genetics, Part A, 2019, 179, 1622-1627.	1.2	7
4	Expression-based decision tree model reveals distinct microRNA expression pattern in pediatric neuronal and mixed neuronal-glial tumors. BMC Cancer, 2019, 19, 544.	2.6	9
5	<p>Artificial microenvironment of in vitro glioblastoma cell cultures changes profile of miRNAs related to tumor drug resistance</p> . OncoTargets and Therapy, 2019, Volume 12, 3905-3918.	2.0	9
6	The Oncogenic Relevance of miR-17-92 Cluster and Its Paralogous miR-106b-25 and miR-106a-363 Clusters in Brain Tumors. International Journal of Molecular Sciences, 2018, 19, 879.	4.1	46
7	Glioblastoma-derived cells <i>in vitro</i> unveil the spectrum of drug resistance capability – comparative study of tumour chemosensitivity in different culture systems. Bioscience Reports, 2017, 37, .	2.4	8
8	Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. PLoS ONE, 2016, 11, e0158464.	2.5	20
9	The molecular pattern of histopathological progression to anaplastic meningioma – A case report. Neurologia I Neurochirurgia Polska, 2016, 50, 288-293.	1.2	1
10	Expression of SOX11, PAX5, TTF-1 and ISL-1 in medulloblastoma. Pathology Research and Practice, 2016, 212, 965-971.	2.3	8
11	The correlation of clinical and chromosomal alterations of benign meningiomas and their recurrences. Neurologia I Neurochirurgia Polska, 2016, 50, 395-402.	1.2	1
12	Recurrence-associated chromosomal anomalies in meningiomas: Single-institution study and a systematic review with meta-analysis. Neurologia I Neurochirurgia Polska, 2016, 50, 439-448.	1.2	8
13	Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathologica, 2016, 131, 847-863.	7.7	143
14	Transcriptional profiles of pilocytic astrocytoma are related to their three different locations, but not to radiological tumor features. BMC Cancer, 2015, 15, 778.	2.6	22
15	Astrocytoma-associated antigens - IL13Rα2, Fra-1, and EphA2 as potential markers to monitor the status of tumour-derived cell cultures in vitro. Cancer Cell International, 2014, 14, 82.	4.1	6
16	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nature Genetics, 2014, 46, 39-44.	21.4	167
17	Novel Gene Expression Model for Outcome Prediction in Paediatric Medulloblastoma. Journal of Molecular Neuroscience, 2013, 51, 371-379.	2.3	6
18	Reduced expression of ELAVL4 in male meningioma patients. Brain Tumor Pathology, 2013, 30, 160-166.	1.7	13

MAGDALENA IZABELA

#	Article	IF	CITATIONS
19	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathologica, 2013, 125, 659-669.	7.7	250
20	Molecular alterations in meningiomas: association with clinical data. , 2013, 32, 114-121.		4
21	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	16.8	1,551
22	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	27.8	2,129
23	Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies. Journal of Neuro-Oncology, 2011, 102, 395-407.	2.9	27
24	Polycomb genes expression as a predictor of poor clinical outcome in children with medulloblastoma. Child's Nervous System, 2011, 27, 79-86.	1.1	17
25	cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer. BMC Cancer, 2009, 9, 278.	2.6	12
26	Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors. BMC Cancer, 2009, 9, 54.	2.6	40
27	Prevalence of mutated TP53 on cDNA (but not on DNA template) in pleomorphic xanthoastrocytoma with positive TP53 immunohistochemistry. Cancer Genetics and Cytogenetics, 2009, 193, 93-97.	1.0	9
28	Successful elimination of non-neural cells and unachievable elimination of glial cells by means of commonly used cell culture manipulations during differentiation of GFAP and SOX2 positive neural progenitors (NHA) to neuronal cells. BMC Biotechnology, 2008, 8, 56.	3.3	10
29	Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53. British Journal of Cancer, 2008, 98, 1431-1433.	6.4	13
30	BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. Cancer Genetics and Cytogenetics, 2008, 183, 14-20.	1.0	20
31	Diverse molecular pattern in a bihemispheric glioblastoma (butterfly glioma) in a 16-year-old boy. Cancer Genetics and Cytogenetics, 2007, 177, 125-130.	1.0	12
32	KCTD11 expression in medulloblastoma is lower than in adult cerebellum and higher than in neural stem cells. Cancer Genetics and Cytogenetics, 2006, 170, 24-28.	1.0	9
33	Mutational analysis of hSNF5/INI1 and TP53 genes in choroid plexus carcinomas. Cancer Genetics and Cytogenetics, 2005, 156, 179-182.	1.0	25
34	Atypical molecular background of glioblastoma and meningioma developed in a patient with Li?Fraumeni syndrome. Journal of Neuro-Oncology, 2005, 71, 27-30.	2.9	22
35	Molecular heterogeneity of meningioma with INI1 mutation. Journal of Clinical Pathology, 2003, 56, 299-301.	1.9	31